**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**WASHINGTON,      D.C. 20549**

**FORM      10-QSB**

| x | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE                ACT OF 1934. |
|---|------------------------------------------------------------------------------------------------------------------|

| o | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE                ACT |
|---|-----------------------------------------------------------------------------------------------|

**NUTRA      PHARMA CORP.**

| **California**                                               | **91-2021600**                                      |
|--------------------------------------------------------------|-----------------------------------------------------|
| (State                or Other Jurisdiction of Organization) | (IRS                Employer Identification Number) |

**791      Park of Commerce Blvd, Suite 300, Boca Raton, FL 33487**

**(954)      509-0911**

----

| PART                I. FINANCIAL INFORMATION                                                                                  |                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                                                                                                                          |                                                                                                    |   |
| Item                1. Financial Statements                                                                                   |                                                                                                    |
|                                                                                                                          |                                                                                                    |   |
|                                                                                                                          | Consolidated                Balance Sheet as of September 30, 2006                                      | 1 |
|                                                                                                                          |                                                                                                    |   |
|                                                                                                                          | Consolidated                Statements of Operations for the three and nine months                ended |   |
|                                                                                                                          | September                30, 2006 and 2005                                                              | 2 |
|                                                                                                                          |                                                                                                    |   |
|                                                                                                                          | Consolidated                Statements of Cash Flows for the nine months ended                          |   |
|                                                                                                                          | September                30, 2006 and 2005                                                              | 3 |
|                                                                                                                          |                                                                                                    |   |
|                                                                                                                          | Notes                to Unaudited Consolidated Financial Statements                                     | 4 |
|                                                                                                                          |                                                                                                    |   |
| Item                2. Management’s Discussion and Analysis of Financial Condition or Plan of                Operations | 9                                                                                                       |
|                                                                                                                          |                                                                                                    |   |
| Item                3. Controls and Procedures                                                                                | 14                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| PART                II. OTHER INFORMATION                                                                                     |                                                                                                    |
|                                                                                                                          |                                                                                                    |   |
| Item                1. Legal Proceedings                                                                                      | 15                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| Item                2. Unregistered Sales of Equity Securities and Use of                Proceeds                             | 15                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| Item                3. Defaults Upon Senior Securities                                                                        | 15                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| Item                4. Submission of Matters to a Vote of Security Holders                                                    | 15                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| Item                5. Other Information                                                                                      | 16                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| Item                6. Exhibits                                                                                               | 16                                                                                                      |
|                                                                                                                          |                                                                                                    |   |
| SIGNATURES                                                                                                                    | 17                                                                                                      |

----

**PART      I FINANCIAL INFORMATION**

**Item      1. Financial Statements**

| ASSETS                                                              |   |   |        |
|---------------------------------------------------------------------|--------|--------|-------------|
| Current                assets:                                      |   |   |        |
| Cash                                                                |   | $      | 53,875      |   |
| Inventory                                                           |   |   | 11,425      |   |
| Total                current assets                                 |   |   | 65,300      |   |
|                                                                |   |   |        |   |
| Property                and equipment, net                          |   |   | 39,585      |   |
|                                                                |   |   |        |   |
| Other                assets                                         |   |   | 34,399      |   |
|                                                                |   |   |        |   |
| TOTAL                ASSETS                                         |   | $      | 139,284     |   |
|                                                                     |   |   |        |   |
|                                                                |   |   |        |   |
| LIABILITIES                AND STOCKHOLDERS' (DEFICIT)              |   |   |        |   |
| Current                liabilities:                                 |   |   |        |   |
| Accounts                payable                                     |   | $      | 101,495     |   |
| Accrued                expenses                                     |   |   | 438,057     |   |
| Due                to officers                                      |   |   | 999,224     |   |
|                                                                |   |   |        |   |
| Total                current liabilities                            |   |   | 1,538,776   |   |
|                                                                |   |   |        |   |
| Stockholders'                (deficit):                             |   |   |        |   |
| Common                stock, $0.001 par value, 2.0 billion shares   |   |   |        |   |
| authorized;                73,211,432 shares issued and outstanding |   |   | 73,211      |   |
| Additional                paid-in capital                           |   |   | 18,000,426  |   |
| (Deficit)                accumulated during the development stage   |   |   | (19,473,129 | ) |
|                                                                |   |   |        |   |
| Total                stockholders' (deficit)                        |   |   | (1,399,492  | ) |
|                                                                     |   |   |        |   |
| TOTAL                LIABILITIES AND STOCKHOLDERS' (DEFICIT)        |   | $      | 139,284     |   |

----

|                                                                 |   | Three                Months Ended September                30, |       | Nine                Months Ended September                30, |   | For                the Period                From February                1, 2000                (Inception)Through                September                30, |   |
|----------------------------------------------------------------------|--------|----------------------------------------------------------------|------------|---------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                 |   | 2005                                                           |       | 2006                                                          |   | 2005                                                                                                                                                            |   | 2006 |   | 2006 |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |
| Sales                                                                |   | $                                                              | -          |                                                          | $      | 400                                                                                                                                                             |   | $ | - |   | $ | 20,200 |   | $ | 20,200 |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Cost                of sales                                         |   |                                                           | -          |                                                          |   | 66                                                                                                                                                              |   |   | - |   |   | 3,472 |   |   | 3,472 |   |
|                                                                 |   |                                                           |       |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | - |   |
| Gross                profit                                          |   |                                                           | -          |                                                          |   | 334                                                                                                                                                             |   |   | - |   |   | 16,728 |   |   | 16,728 |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Costs                and expenses:                                   |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| General                and administrative                            |   |                                                           | 419,299    |                                                          |   | 340,191                                                                                                                                                         |   |   | 1,328,488 |   |   | 1,047,339 |   |   | 6,037,840 |   |
| Research                and development                              |   |                                                           | 66,320     |                                                          |   | 181,617                                                                                                                                                         |   |   | 171,819 |   |   | 331,750 |   |   | 1,661,067 |   |
| General                and administrative - stock based compensation |   |                                                           | 555,385    |                                                          |   | 85,053                                                                                                                                                          |   |   | 1,355,190 |   |   | 597,803 |   |   | 6,318,989 |   |
| Write-off                of advances to potential acquiree           |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 629,000 |   |
| Finance                costs                                         |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 786,000 |   |
| Interest                expense                                      |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | 269,684 |   |   | - |   |   | 274,390 |   |
| Amortization                of license agreement                     |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 155,210 |   |
| Amortization                of intangibles                           |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 656,732 |   |
| Losses                on settlements                                 |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 1,261,284 |   |
| Write-down                of investment in subsidiary                |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 620,805 |   |
| Equity                in loss of unconsolidated subsidiary           |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 853,540 |   |
| Write-off                of investment in Portage BioMed             |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 60,000 |   |
| Write-off                of investment in Xenacare                   |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | 175,000 |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Total                costs and expenses                              |   |                                                           | 1,041,004  |                                                          |   | 606,861                                                                                                                                                         |   |   | 3,125,181 |   |   | 1,976,892 |   |   | 19,489,857 |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Net                loss before provision (benefit) for income taxes  |   |                                                           | (1,041,004 | )                                                             |   | (606,527                                                                                                                                                        | )      |   | (3,125,181 | ) |   | (1,960,164 | ) |   | (19,473,129 | ) |
| Provision                (benefit) for income taxes                  |   |                                                           | -          |                                                          |   | -                                                                                                                                                               |   |   | - |   |   | - |   |   | - |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                              |   | $                                                              | (1,041,004 | )                                                             | $      | (606,527                                                                                                                                                        | )      | $ | (3,125,181 | ) | $ | (1,960,164 | ) | $ | (19,473,129 | ) |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Per                share information - basic and diluted:            |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Loss                per common share                                 |   | $                                                              | (0.02      | )                                                             | $      | (0.01                                                                                                                                                           | )      | $ | (0.05 | ) | $ | (0.03 | ) |   |   |   |
|                                                                 |   |                                                           |       |                                                          |   |                                                                                                                                                            |   |   |   |   |   |   |   |   |   |   |
| Weighted                average common shares outstanding            |   |                                                           | 67,900,878 |                                                          |   | 72,520,021                                                                                                                                                      |   |   | 62,863,086 |   |   | 71,092,017 |   |   |   |   |

----

NUTRA      PHARMA CORP.

|                                                              |   | Nine                Months EndedSeptember                30, |       | For                the Period                FromFebruary                1, 2000(Inception)                ThroughSeptember                30, |   |
|-------------------------------------------------------------------|--------|--------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                              |   | 2005                                                         |       | 2006                                                                                                                                           |   | 2006 |   |
| Cash                flows from operating activities:              |   |                                                         |       |                                                                                                                                           |   |   |   |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |
| Net                cash (used in) operating activities            |   | $                                                            | (1,369,678 | )                                                                                                                                              | $      | (1,398,054 | ) | $ | (4,543,718 | ) |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Cash                flows from investing activities:              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Cash                reduction due to deconsolidation of Nanologix |   |                                                         | -          |                                                                                                                                           |   | - |   |   | (2,997 | ) |
| Cash                acquired in acquisition of Nanologix          |   |                                                         | -          |                                                                                                                                           |   | - |   |   | 3,004 |   |
| Acquisition                of property and equipment              |   |                                                         | (5,114     | )                                                                                                                                              |   | - |   |   | (86,140 | ) |
| Amounts                paid for investments                       |   |                                                         | (130,000   | )                                                                                                                                              |   | - |   |   | (235,000 | ) |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Net                cash (used in) investing activities            |   |                                                         | (135,114   | )                                                                                                                                              |   | - |   |   | (321,133 | ) |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Cash                flows from financing activities:              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Common                stock issued for cash                       |   |                                                         | 1,079,800  |                                                                                                                                           |   | 622,000 |   |   | 2,679,500 |   |
| Proceeds                from convertible loans                    |   |                                                         | -          |                                                                                                                                           |   | - |   |   | 304,750 |   |
| Loans                from stockholders, net of repayments         |   |                                                         | 33,000     |                                                                                                                                           |   | 760,902 |   |   | 1,934,476 |   |
|                                                                   |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Net                cash provided by financing activities          |   |                                                         | 1,112,800  |                                                                                                                                           |   | 1,382,902 |   |   | 4,918,726 |   |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Net                increase (decrease) in cash                    |   |                                                         | (391,992   | )                                                                                                                                              |   | (15,152 | ) |   | 53,875 |   |
| Cash                - beginning of period                         |   |                                                         | 409,432    |                                                                                                                                           |   | 69,027 |   |   | - |   |
|                                                              |   |                                                         |       |                                                                                                                                           |   |   |   |   |   |   |
| Cash                - end of period                               |   | $                                                            | 17,440     |                                                                                                                                           | $      | 53,875 |   | $ | 53,875 |   |

----

----

----

----

|                                         |   | Numberofshares |      | Weightedaverage                exerciseprice |   | Weightedaveragefairvalue |   |
|----------------------------------------------|--------|----------------|-----------|----------------------------------------------|--------|--------------------------|--------|
| Balance                at December 31, 2005  |   |           | -         |                                         |   |                     |   |   |   |   |
| Issued                                       |   |           | 3,000,000 |                                         | $      | .25                      |   | $ | .16 |   |
| Balance                at September 30, 2006 |   |           | 3,000,000 |                                         | $      | .25                      |   | $ | .16 |   |

**:**

|           |   |                                   |            | Outstanding                          |   |
|----------------|--------|----------------------------------------|-----------------|--------------------------------------|--------|
| ExercisePrices |   | WeightedAverageNumberOutstanding  |            | WeightedAverageContractual Life |   | Weighted-AverageExercise Price |   |
| $.20           |   |                                   | 1,000,000       |                                 |   | 4.3                years |   | $ | .20 |   |
| $.27           |   |                                   | 2,000,000       |                                 |   | 1.5                years |   | $ | .27 |   |
|                |   |                                   | 3,000,000  |                                 |   |   |   |   |   |   |

----

----

----

| ·   | Successful                drugs by our competitors that may render our technologies difficult                to                market; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Whether                we are successful in establishing licensing agreements and/or establishing                strategic partnerships or alliances with pharmaceutical companies,                biotechnology companies, and clinical diagnostic laboratories that                would                provide us with licensing fees; and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| ·   | Whether                the Federal Food and Drug Administration imposes additional requirements                in connection with drug approvals, which will lead to additional                costs and                delays; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

PLAN      OF      OPERATIONS

| Type                Expenditure                                        |   | Total Expenditure                  |    | Monthly Expenditure |   |
|------------------------------------------------------------------------|--------|----------------------------------------------|---------|--------------------------|--------|
|                                                                   |   |                                         |    |                     |   |
| Salaries*                                                              |   | $                                            | 175,000 |                     | $      | 14,583 |   |
|                                                                   |   |                                         |    |                     |   |   |   |
| Travel                related expenses for our Chief Executive Officer |   | $                                            | 40,000  |                     | $      | 3,333 |   |
| pertaining                to research and due diligence                |   |                                         |    |                     |   |   |   |
|                                                                   |   |                                         |    |                     |   |   |   |
| Professional                Fees -Legal and                Accounting  |   | $                                            | 165,000 |                     | $      | 13,750 |   |
|                                                                   |   |                                         |    |                     |   |   |   |
| Total                                                                  |   | $                                            | 380,000 |                     | $      | 31,666 |   |

| Type                Expenditure              |   | TotalExpenditure |    | MonthlyExpenditure |   |
|--------------------------------------------------------|--------|------------------|---------|--------------------|--------|
|                                                   |   |             |    |               |   |
| Operating                Expenses                      |   |             |    |               |   |
| (Rent,                supplies, utilities)   |   | $                | 50,000  |               | $      | 4,167 |   |
| Salaries                (President)          |   | $                | 70,000  |               | $      | 5,833 |   |
| Total:                                       |   | $                | 120,000 |               | $      | 10,000 |   |

----

| ·   | In                February 2006, we completed the initial funding of ReceptoPharm in                the                amount of $2,000,000. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | In                January 2006, we established Designer Diagnostics to sell NonTuberculois                Mycobacterium test kits. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | To                date, we have invested a total of $175,000 of a $250,000 committed                investment in XenaCare for the investment in 15 Site of Care physician’s                offices with XenaCare, LLC, a healthcare management                company. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | On                January 24, 2006, we obtained NanoLogix’s intellectual property pertaining                to the manufacture of test kits for the rapid isolation, detection                and                antibiotic sensitivity testing of certain microbacteria, which includes                reassignment to us of 11 key patents protecting the diagnostics test                kit                technology and NanoLogix licensing to us the remaining 18 patents                that                protect the diagnostics test kit                technology. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Designer                Diagnostics held a Continuing Medical Education Seminar at the Mahatma                Gandhi Institute in India on March 24, 2006 during the World Stop                TB Day.                At that meeting, Designer Diagnostics officially began marketing                their                test kits for the rapid isolation, detection and antibiotic-sensitivity                testing of microbacteria. In March 2006, we made our first sales                of                Designer Diagnostics’ test kits. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | In                approximately October 2005, we completed pre-clinical studies with                various                companies that ReceptoPharm has agreements with pertaining to                ReceptoPharm’s Multiple Sclerosis (MS) and HIV drugs, which consisted of                (a) and (b) below: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | In                May of 2006, ReceptoPharm, received approval from the Medicines Health                and                Regulatory Agency (MHRA) for its application of human clinical trials                for                the treatment of Adrenomyeloneuropathy (AMN). The MHRA is the medical                regulatory agency within the British Department of                Health. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | From                March and April of 2006, ReceptoPharm published two clinical trials                on the                use of their technology in the treatment of                pain. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| ·   | In                June of 2006, ReceptoPharm published the results of their EAE rat                model of                Multiple Sclerosis (MS), which showed that their drug, RPI-78M, had                promising results in an accepted animal model of the                disease. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| ·   | In                June of 2006, ReceptoPharm signed a non-binding Letter-of-Intent                to be                acquired in full by Nutra Pharma. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | In                October of 2006, ReceptoPharm received Ethics Committee approval                in the UK                to begin its Phase IIb human clinical trial for the treatment of                AMN. This                approval allows for the late Phase II/early Phase III (IIb/IIIa)                trial to                begin. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

*Designer      Diagnostics, Inc.*

| ·   | Hospitals; |
|--------------------|------------|

|   |   |
|--------|--------|
| ·   | Pharmaceutical                companies; |
|--------------------|------------------------------------------|

|   |   |
|--------|--------|
| ·   | Biotechnology                companies; |
|--------------------|-----------------------------------------|

|   |   |
|--------|--------|
| ·   | Medical                device distributors; and |
|--------------------|-------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Governmental                organizations. |
|--------------------|--------------------------------------------|

*Designer      Diagnostics’ President*

----

*ReceptoPharm*

| ·   | Recruitment                of 20 patients with AMN; |
|--------------------|-----------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Administering                ReceptoPharm's AMN drug under development;                and |
|--------------------|--------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| ·   | Monitoring                patients throughout a 15-month                protocol. |
|--------------------|-----------------------------------------------------------------------------------|

*Acquisition      of ReceptoPharm*

----

| ·   | Sell                or dispose of our assets, if any; |
|--------------------|-------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Pay                our liabilities in order of priority, if we have available cash to                pay                such liabilities; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | If                any cash remains after we satisfy amounts due to our creditors, distribute                any remaining cash to our shareholders in an amount equal to the net                market value of our net assets; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | File                a Certificate of Dissolution with the State of California to dissolve                our                corporation and close our business; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Make                the appropriate filings with the Securities and Exchange Commission                so                that we will no longer be required to file periodic and other required                reports with the Securities and Exchange Commission, if, in fact,                we are a                reporting company at that time; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Make                the appropriate filings with the Securities and Exchange Commission                so                that we will no longer be required to file periodic and other required                reports with the Securities and Exchange Commission, if, in fact,                we are a                reporting company at that time; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Make                the appropriate filings with the National Association of Security                Dealers                to effect a delisting of our common stock, if, in fact, our common                stock                is trading on the Over-the-Counter Bulletin Board at that                time. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

PART      II.      OTHER INFORMATION 

Item      1.      Legal Proceedings 

| ·   | We                are not and were not a blank check company at the time of the offer                or                sale; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | The                investors had business experience and were accredited investors as                defined                by Rule 501 of Regulation D of the                Act; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | All                offers and sales of the investment were made privately and no party                engaged in any general solicitation or advertising of the proposed                investment; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | Each                investor had a preexisting social, personal or business relationship                with                us and members of our management; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | The                investors were provided with all information sufficient to allow                them to                make an informed investment                decision; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | The                investors had the opportunity to inspect our books and records and                to                verify statements made to induce them to                invest; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | The                securities representing the investment were issued with a restrictive                legend indicating the securities represented by the certificate have                not                been registered; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| ·   | No                party received any transaction-based compensation such as commissions                in                regard to locating any investor for the                venture. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Item      4.      Submission of Matters to a Vote of Security Holders 

----

| Exhibit                No. |   | Title                                                                                                                                                                                                                                      |
|----------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                       |   |                                                                                                                                                                                                                                       |
| 31.1                       |   | Certification                of Chief Executive Officer and Chief Financial Officer pursuant to                Section                302 of the Sarbanes-Oxley Act of 2002.                                                               |
|                       |   |                                                                                                                                                                                                                                       |
| 32.1                       |   | Certification                of Chief Executive Officer and Chief Financial Officer pursuant to                18                U.S.C. Section 1350, as adopted pursuant to Section 906 of the                Sarbanes-Oxley Act of 2002. |

----

|                                                             |   |   |   |
|------------------------------------------------------------------|--------|--------|--------|
| Dated: November 14,              2006                            |   |   |   |
|                                                             |   |   |   |
| NUTRA                PHARMA CORP.Registrant                      |   |   |   |
|                                                             |   |   |   |
| /s/ Rik J. Deitsch                                               |   |   |        |
| Rik              J. Deitsch                                      |   |   |        |
| Chief Executive Officer and Chief Financial              Officer |   |   |        |

----